Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

While Wegovy (semaglutide) sales more than doubled to DKK 19.87 billion ($2.78 billion) in the three-month period, that was slightly below estimates and Novo Nordisk said is now anticipating ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Novo Nordisk A/S soared the most since August 2023 after an experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.

Amycretin affects the same two targets as a Novo drug called cagrisema that recently missed expectations in a Phase 3 trial, ...

Novo Nordisk A/S soared the most since August after an experimental shot delivered as much as 22% weight loss in an ...